The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Elevated Chlamydia pneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction
Abstract
Background The clinical significance of the association between elevated anti– Chlamydia pneumoniae (Cp) antibody titres and coronary heart disease (CHD) is unclear. We explored the relationship between antibodies against Cp and future cardiovascular events in male survivors of myocardial infarction (MI). The effect of azithromycin antibiotic therapy was assessed in a subgroup of post-MI patients. Methods and Results We screened 220 consecutive male survivors of MI for anti-Cp antibodies. Of these, 213 patients were stratified into three groups: group Cp-ve (n=59), no detectable Cp antibodies; group Cp-I (n=74), intermediate titres of 1/8 to 1/32 dilution; and group Cp+ve (n=80), seropositive at ≥1/64 dilution. Patients with persisting seropositivity of ≥1/64 were randomized to either oral azithromycin (Cp+ve-A, 500 mg/d for 3 days [n=28] or 500 mg/d for 6 days [n=12]) or placebo (Cp+ve-P, n=20). Cp+ve-NR (n=20) represented patients not recruited into the antibiotic trial. The incidence of adverse cardiovascular events (over a mean follow-up period of 18±4 months) was recorded and shown to increase with increasing anti-Cp titre: Cp-ve, n=4 (7%); Cp-I, n=11 (15%); Cp+ve-NR, n=6 (30%); and Cp+ve-P, n=5 (25%). Cp+ve-NR and Cp+ve-P groups had a fourfold-increased risk for adverse cardiovascular events compared with the Cp-ve group (odds ratio [OR], 4.2; 95% confidence interval [CI], 1.2 to 15.5; P =.03). In contrast, the OR for cardiovascular events in patients receiving azithromycin (Cp+ve-A, single or double course) was the same as in the Cp-ve group (OR, 0.9; 95% CI, 0.2 to 4.6, P =NS). Patients receiving azithromycin were more likely to experience a decrease in IgG anti-Cp titres than were those in the placebo group ( P =.02). Conclusions An increased anti-Cp antibody titre may be a predictor for further adverse cardiovascular events in post-MI patients. Taking a short course of azithromycin may lower this risk, possibly by acting against Cp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Atherosclerosis — An Update
Ross, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140806 · Cited by 4,877
Saikku, P., Mattila, K., Nieminen, M. S., Huttunen, J. K., Leinonen, M., Ekman, M.-R., Mäkelä, P. H., & Valtonen, V (1988) · The Lancet · doi:10.1016/s0140-6736(88)90741-6 · Cited by 1,964
Saikku, P., Leinonen, M., Tenkanen, L., Linnanmäki, E., Ekman, M.-R., Manninen, V., Mänttäri, M., Frick, M. H., & Huttunen, J. K. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-4-273 · Cited by 786
Demonstration of Chlamydia pneumoniae in Atherosclerotic Lesions of Coronary Arteries
Kuo, C.-C., Shor, A., Campbell, L. A., Fukushi, H., Patton, D. L., & Grayston, J. T. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.4.841 · Cited by 762
The pharmacokinetics of azithromycin in human serum and tissues
Foulds, G., Shepard, R. M., & Johnson, R. B. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.suppl_a.73 · Cited by 755
Patel, P., Mendall, M. A., Carrington, D., Strachan, D. P., Leatham, E., Molineaux, N., Levy, J., Blakeston, C., Seymour, C. A., Camm, A. J., et al. (1995) · BMJ · doi:10.1136/bmj.311.7007.711 · Cited by 592
Self-citationAssociation of serum antibodies to heat-shock protein 65 with carotid atherosclerosis
Xu, Q., Wick, G., Willeit, J., Marosi, M., Kiechl, S., Luef, G., Kleindienst, R., Stulnig, T., Wick, G., & Oberhollenzer, F. (1993) · The Lancet · doi:10.1016/0140-6736(93)92613-x · Cited by 514
Muhlestein, J. B., Hammond, E. H., Carlquist, J. F., Radicke, E., Thomson, M. J., Karagounis, L. A., Woods, M. L., & Anderson, J. L. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00055-1 · Cited by 420
Thom, D. H. (1992) · JAMA · doi:10.1001/jama.268.1.68 · Cited by 397
Detection of Chlamydia pneumoniae TWAR in Human Coronary Atherectomy Tissues
Campbell, L. A., O'Brien, E. R., Cappuccio, A. L., Kuo, C.-C., Wang, S.-P., Stewart, D., Patton, D. L., Cummings, P. K., & Grayston, J. T. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/172.2.585 · Cited by 346
Thom, D. H. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490010070032 · Cited by 316
Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis
Melnick, S. L., Shahar, E., Folsom, A. R., Grayston, J. T., Sorlie, P. D., Wang, S.-P., & Szklo, M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90332-j · Cited by 245
Clinical toleration and safety of azithromycin
Hopkins, S. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90401-i · Cited by 233
Randomised controlled trial of single-dose azithromycin in treatment of trachoma
Bailey, R. L., Arullendran, P., Mabey, D. C. W., & Whittle, H. C. (1993) · The Lancet · doi:10.1016/0140-6736(93)91591-9 · Cited by 231
Chlamydia pneumoniae: Risk factors for seropositivity and association with coronary heart disease
Mendall, M. A., Carrington, D., Strachan, D., Patel, P., Molineaux, N., Levi, J., Toosey, T., Camm, A. J., & Northfield, T. C. (1995) · Journal of Infection · doi:10.1016/s0163-4453(95)80006-9 · Cited by 192
Self-citationIncreased monocyte tissue factor expression in coronary disease.
Leatham, E. W., Bath, P. M., Tooze, J. A., et al. (1995) · Heart · doi:10.1136/hrt.73.1.10 · Cited by 157
Self-citationFibrinogen: a link between chronic infection and coronary heart disease
Patel, P., Carrington, D., Strachan, D. P., Leatham, E. W., Goggin, P., Northfield, T. C., & Mendall, M. A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)93084-8 · Cited by 144
Self-citationEfficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia
Rizzato, G., Montemurro, L. A., Fraioli, P., Montanari, G., Fanti, D., Pozzoli, R., & Magliano, E. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08030398 · Cited by 75
Cited by
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., et al. (2006) · Stroke · doi:10.1161/01.str.0000223048.70103.f1 · Cited by 1,368
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
Identification of Periodontal Pathogens in Atheromatous Plaques
Haraszthy, V. I., Zambon, J. J., Trevisan, M., Zeid, M., & Genco, R. J. (2000) · Journal of Periodontology · doi:10.1902/jop.2000.71.10.1554 · Cited by 1,120
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 905
Metadata
- Authors
- Gupta, S., Leatham, E. W., Carrington, D., Mendall, M. A., Kaski, J. C., & Camm, A. J.
- Venue
- Circulation
- Published
- 1997-07-15
- Volume
- 96
- Issue
- 2
- Pages
- 404-407
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2061940963
- Cited by
- 706
- References
- 18
- FWCI
- 39.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.